A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
← catalyst calendarNCT03460977 · readout in 610 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
453estimated
Sites
82
Countries
Bulgaria, China, Japan +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-04-17 | actual | When the study began enrolling |
| Primary completion | 2028-04-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-07 | estimated | The whole study's end, after follow-up |
| First posted | 2018-03-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Small Cell Lung Cancer (SCLC)
- Follicular Lymphoma (FL)
Interventions
- Drug: Mervometostat (PF-06821497) — also filed as EZH2i
- Drug: Enzalutamide — also filed as Xtandi
- Drug: Itraconazole — also filed as Sporanox, Tolsura, Onmel
Primary outcomes
what the primary-completion date above is the date OFPercentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
measured Baseline up to 90 days
Overall safety profile including adverse events
measured Baseline up to approximately 2 years
Preliminary efficacy determination as evaluated by disease specific response criteria
measured Through study completion, approximately 2 years past last patient first visit.
Overall safety profile including laboratory abnormalities
measured Baseline up to approximately 2 years
Overall safety profile including vital signs
measured Baseline up to approximately 2 years
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
measured Baseline until disease progression or death or through study completion (approx 2 years)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed